Shire, the global specialty biopharmaceutical company, recently announced its acquisition of Lotus Tissue Repair and their recombinant collagen VII protein replacement therapy which is in development for the treatment of DEB. Following this recent announcement, Dr. Anil S. Jina, Vice President and Head of Global Medical Affairs at Shire, attended DEBRA Ireland’s family day on May 12th.
Dr. Jina provided the 80 family members and DEBRA supporters with an insight into Shire and the company’s strong focus on rare diseases. He also outlined the commitment of the company to continue to progress the development of recombinant collagen VII protein therapy, previously in development by Lotus Tissue Repair for the treatment of DEB. For the Irish families living with EB, a first-hand account of Shire’s commitment to developing this treatment was very welcome. One father commented that he thought he would ‘never see the day that a pharmaceutical company would show that level of interest in EB’. Dr. Jina had the opportunity to meet with many of the families at the meeting and to learn more about their lives with EB.
The family day was held at Killashee House, the location of ‘Emma’s Butterfly Garden’. The stunning garden, dedicated to people affected by EB, was in full bloom and provided a lovely backdrop to the meeting. The day also doubled as a celebration of DEBRA Ireland’s 25th year anniversary.